DBL™ Adrenaline Injection BP

Valsts: Jaunzēlande

Valoda: angļu

Klimata pārmaiņas: Medsafe (Medicines Safety Authority)

Aktīvā sastāvdaļa:

Adrenaline acid tartrate 1.8mg equivalent to 1:10000 or 1 mg/10mL adrenaline

Pieejams no:

Pfizer New Zealand Limited

SNN (starptautisko nepatentēto nosaukumu):

Adrenaline acid tartrate 1.8 mg (Equiv to 1:10000 or 1 mg/10mL adrenaline)

Deva:

1:10000

Zāļu forma:

Solution for injection

Kompozīcija:

Active: Adrenaline acid tartrate 1.8mg equivalent to 1:10000 or 1 mg/10mL adrenaline Excipient: Sodium chloride Sodium metabisulfite Water for injection

Vienības iepakojumā:

Ampoule, glass, 10mL, 5 dose units

Klase:

Restricted

Receptes veids:

Restricted

Ražojis:

Boehringer Ingelheim Pharma GmbH & Co KG

Ārstēšanas norādes:

For the treatment of acute allergic reactions, life-threatening angioneurotic oedema, and anaphylactic shock resulting from reactions to drugs, animal serums, insect stings and other allergens.

Produktu pārskats:

Package - Contents - Shelf Life: Ampoule, glass, 10mL - 5 dose units - 18 months from date of manufacture stored at or below 25°C - Ampoule, glass, 10mL - 50 dose units - 18 months from date of manufacture stored at or below 25°C

Autorizācija datums:

1984-03-08

Produkta apraksts

Version: pfdadrni10721
Supersedes: pfdadrni10219
Page 1 of 11
NEW ZEALAND DATA SHEET
1.
PRODUCT NAME
DBL™ Adrenaline 1:1000 (1 mg/mL) and 1:10,000 (1 mg/10 mL) solution
for injection.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
DBL Adrenaline 1:1000 (1 mg/mL) and 1:10,000 (1 mg/10 mL) solution for
injection is a
sterile, clear, colourless aqueous solution.
Each ampoule of DBL Adrenaline Injection 1:1,000 contains 1.8 mg of
adrenaline acid tartrate
(equivalent to 1 mg of adrenaline)/mL of water.
Each ampoule of DBL Adrenaline Injection 1:10,000 contains 1.8 mg of
adrenaline acid
tartrate (equivalent to 1 mg of adrenaline)/10 mL of water.
EXCIPIENT(S) WITH KNOWN EFFECT
Each ampoule contains 1 mg/mL of sodium metabisulfite and 8 mg/mL of
sodium chloride.
For full list of excipients, see Section 6.1 List of excipients.
3.
PHARMACEUTICAL FORM
Solution for injection.
4.
CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS
DBL ADRENALINE 1:1,000
For the treatment of acute allergic reactions, life-threatening
angioneurotic oedema and
anaphylactic shock resulting from reactions to drugs, animal serums,
insect stings and other
allergens.
DBL ADRENALINE 1:10,000
Adjunctive use in the management of cardiac arrest and anaphylactic
shock resulting from
reactions to drugs, animal serums, insect stings and other allergens.
4.2 DOSE AND METHOD OF ADMINISTRATION
DBL Adrenaline injection does not contain any preservatives. It is for
single use in one patient
only. Discard any residue.
Do not use if the injection is brown or contains a precipitate.
Version: pfdadrni10721
Supersedes: pfdadrni10219
Page 2 of 11
Adrenaline is given by subcutaneous injection. It may also be
administered intramuscularly but
not into the buttocks.
In extreme emergencies, where a more rapid effect is required,
adrenaline may be given by
slow intravenous injection or by slow intravenous infusion but
ONLY AS A DILUTE SOLUTION (1 IN
10,000 OR 1 IN 100,000).
ACUTE ALLERGIC REACTIONS, LIFE-THREATENING ANGIONEUROTIC OEDEMA AND
ANAPHYLACTIC SHOCK
DBL ADRENALINE 1:1